SCUEL — Japan healthcare data

HomeTherapeutic areas › Antimetabolites

Japan market screening · Therapeutic class

Antimetabolites in Japan

代謝拮抗剤 · Japan Standard Commodity Classification

15 molecules in this class are marketed in Japan across 71 products. 3 of those products are not shipping normally today — 4.2% of the class. Supply status is reported to the Ministry of Health, Labour and Welfare and updated daily.

15Molecules
71Marketed products
3Products constrained

Molecules in this class

Ordered by how many products compete. Constrained means limited supply or supply suspended; supply suspended does not mean discontinued.

MoleculeProducts CompaniesConstrained Supply mix
Pemetrexed Sodium Hemipentahydrateペメトレキセドナトリウムヘミペンタ水和物2471
Gemcitabine Hydrochlorideゲムシタビン塩酸塩1032
Cytarabineシタラビン92
Capecitabineカペシタビン77
Fluorouracilフルオロウラシル52
Tegafur / Uracilテガフール・ウラシル41
Enocitabineエノシタビン31
Fludarabine Phosphateフルダラビンリン酸エステル21
Clofarabineクロファラビン11
Cytarabine Ocfosfate Hydrateシタラビン オクホスファート水和物11
Doxifluridineドキシフルリジン11
Hydroxycarbamideヒドロキシカルバミド11
Mercaptopurine Hydrateメルカプトプリン水和物11
Nelarabineネララビン11
Pralatrexateプララトレキサート11
Normal supply Limited supply Supply suspended

How to read this

Products counts every marketed product across all strengths and forms, not companies. Companies is the number of companies marketing that molecule; the same company may appear under several molecules, so the column does not add up to a class total. Market size sits on each molecule's own page, valued at national price rather than transaction price. Figures are as at 2026-08-28.

Screening this area in Japan?

Tell us which molecules matter to you. We will tell you what the public data can and cannot answer before you commission anything.

Send an enquiry

Our Database Division replies in English within three business days (Japan time).